BRIEF-Precigen Reports Durable Responses With Papzimeos in Recurrent Respiratory Papillomatosis

Reuters

Oct 13

BRIEF-<a href="https://laohu8.com/S/PGEN">Precigen</a> Reports Durable Responses With Papzimeos in Recurrent Respiratory Papillomatosis

Oct 13 (Reuters) - Precigen Inc PGEN.O:

PRECIGEN ANNOUNCES LONG-TERM FOLLOW-UP RESULTS HIGHLIGHTING ONGOING DURABLE COMPLETE RESPONSES AFTER TREATMENT WITH PAPZIMEOS, THE FIRST AND ONLY FDA-APPROVED THERAPY FOR ADULTS WITH RECURRENT RESPIRATORY PAPILLOMATOSIS
PRECIGEN INC - 83% OF RESPONDERS SHOW CONTINUED COMPLETE RESPONSE AFTER 36 MONTHS
PRECIGEN INC - SURGERY REDUCTION OBSERVED IN 95% OF PATIENTS BY YEAR 3
PRECIGEN INC - NO NEW SAFETY EVENTS OBSERVED DURING LONG-TERM FOLLOW-UP

Source text: ID:nPn1Sk4yHa

Further company coverage: PGEN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575587408"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575587408\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575587408?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 19:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575587408","market":"fut","top_or_hot":-1,"title":"BRIEF-Precigen Reports Durable Responses With Papzimeos in Recurrent Respiratory Papillomatosis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PGEN\">Precigen</a> Reports Durable Responses With Papzimeos in Recurrent Respiratory Papillomatosis</title></head><body><p><span>Oct 13 (Reuters)</span><span> - </span>Precigen Inc <span>PGEN.O</span>:</p><ul><li><p>PRECIGEN ANNOUNCES LONG-TERM FOLLOW-UP RESULTS HIGHLIGHTING ONGOING DURABLE COMPLETE RESPONSES AFTER TREATMENT WITH PAPZIMEOS, THE FIRST AND ONLY FDA-APPROVED THERAPY FOR ADULTS WITH RECURRENT RESPIRATORY PAPILLOMATOSIS</p></li><li><p>PRECIGEN INC - 83% OF RESPONDERS SHOW CONTINUED COMPLETE RESPONSE AFTER 36 MONTHS</p></li><li><p>PRECIGEN INC - SURGERY REDUCTION OBSERVED IN 95% OF PATIENTS BY YEAR 3</p></li><li><p>PRECIGEN INC - NO NEW SAFETY EVENTS OBSERVED DURING LONG-TERM FOLLOW-UP</p></li></ul><p>Source text: <span>ID:nPn1Sk4yHa</span></p><p>Further company coverage: <span>PGEN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Precigen Reports Durable Responses With Papzimeos in Recurrent Respiratory Papillomatosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Precigen Reports Durable Responses With Papzimeos in Recurrent Respiratory Papillomatosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-13 19:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PGEN\">Precigen</a> Reports Durable Responses With Papzimeos in Recurrent Respiratory Papillomatosis</title></head><body><p><span>Oct 13 (Reuters)</span><span> - </span>Precigen Inc <span>PGEN.O</span>:</p><ul><li><p>PRECIGEN ANNOUNCES LONG-TERM FOLLOW-UP RESULTS HIGHLIGHTING ONGOING DURABLE COMPLETE RESPONSES AFTER TREATMENT WITH PAPZIMEOS, THE FIRST AND ONLY FDA-APPROVED THERAPY FOR ADULTS WITH RECURRENT RESPIRATORY PAPILLOMATOSIS</p></li><li><p>PRECIGEN INC - 83% OF RESPONDERS SHOW CONTINUED COMPLETE RESPONSE AFTER 36 MONTHS</p></li><li><p>PRECIGEN INC - SURGERY REDUCTION OBSERVED IN 95% OF PATIENTS BY YEAR 3</p></li><li><p>PRECIGEN INC - NO NEW SAFETY EVENTS OBSERVED DURING LONG-TERM FOLLOW-UP</p></li></ul><p>Source text: <span>ID:nPn1Sk4yHa</span></p><p>Further company coverage: <span>PGEN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUA5ZRPSP:1","article_id":"2575587408","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575587408","pubTimestamp":1760353880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Precigen Reports Durable Responses With Papzimeos in Recurrent Respiratory PapillomatosisOct 13 (Reuters) - Precigen Inc PGEN.O:PRECIGEN ANNOUNCES LONG-TERM FOLLOW-UP RESULTS HIGHLIGHTING ONGOIN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PGEN":"Precigen"},"translate_title":"BRIEF-Precigen报告Papzimeos治疗复发性呼吸道乳头状瘤病的持久疗效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGEN":0.9},"content_text":"BRIEF-Precigen Reports Durable Responses With Papzimeos in Recurrent Respiratory PapillomatosisOct 13 (Reuters) - Precigen Inc PGEN.O:PRECIGEN ANNOUNCES LONG-TERM FOLLOW-UP RESULTS HIGHLIGHTING ONGOING DURABLE COMPLETE RESPONSES AFTER TREATMENT WITH PAPZIMEOS, THE FIRST AND ONLY FDA-APPROVED THERAPY FOR ADULTS WITH RECURRENT RESPIRATORY PAPILLOMATOSISPRECIGEN INC - 83% OF RESPONDERS SHOW CONTINUED COMPLETE RESPONSE AFTER 36 MONTHSPRECIGEN INC - SURGERY REDUCTION OBSERVED IN 95% OF PATIENTS BY YEAR 3PRECIGEN INC - NO NEW SAFETY EVENTS OBSERVED DURING LONG-TERM FOLLOW-UPSource text: ID:nPn1Sk4yHaFurther company coverage: PGEN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}